When Sanofi terminated its partnership with Maze Therapeutics this week to develop an experimental drug for Pompe disease, Maze CEO Jason Coloma did not learn the news in a conference call with the French pharma giant or even an email. He found out when Sanofi issued a public statement.
Responding to the U.S. Federal Trade Commission’s move to block the licensing deal, Sanofi said it disagreed with the agency’s action, but determined that fighting it in court was “not in the best interest of patients.”
Coloma told STAT he was “personally disappointed that we didn’t get to see this through.”
